TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01033175

Intervention type: PROCEDURE
Group type: OTHER
Intervention: maximal cardiopulmonary exercise testing
Description: Cardiopulmonary exercise testing (CPET) will be performed on a cyclic ergometer with continuous monitoring of a 12-lead electrocardiogram, heart rate and blood pressure. While breathing with a mask, the patients will perform a ramp protocol which includes 2-minutes free pedaling and progressive increase of power by 10, 15 or 20 watts/minute; power size will be selected after considering the patient' s daily activity and parameters of pulmonary function. CPET will be performed until exhaustion, unless the subjects reveal symptoms or signs indicating the exercise should stop (e.g. severe breathlessness).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: maximal cardiopulmonary exercise testing
Description: Cardiopulmonary exercise testing (CPET) will be performed on a cyclic ergometer with continuous monitoring of a 12-lead electrocardiogram, heart rate and blood pressure. While breathing with a mask, the patients will perform a ramp protocol which includes 2-minutes free pedaling and progressive increase of power by 10, 15 or 20 watts/minute; power size will be selected after considering the patient' s daily activity and parameters of pulmonary function. CPET will be performed until exhaustion, unless the subjects reveal symptoms or signs indicating the exercise should stop (e.g. severe breathlessness).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: peripheral blood samples
Description: Peripheral venous blood samples will be collected again in the morning after a fasting period of ≥12 hours. After immediate centrifugation, aliquots will be stored at -75˚C until analysis. Inflammatory markers and erythropoietin will be analyzed by flow cytometry and by enzyme-linked immunosorbent assay, using commercially available kits.
Study: NCT03788889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital
Description: Phenobarbital intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Standard of Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Standard of Care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lorazepam
Description: Standard of Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo A
Description: Placebo injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo A
Description: Placebo injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo B
Description: Placebo infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo B
Description: Placebo infusion
Study: NCT04795271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthopedic intervention
Description: In each custom insole, modifications can be included in the following aspects according to the requirements of each participant :~1. Forefoot specifications: a) Retrocapital bar, b) Retrocapital support, c) Claw toe correction element, d) Pronating wedge, e) Supinator wedge, f) Metatarsal head pad, g) Selective perforations in the insole, h) Others.~2. Midfoot specifications: a) Internal arch, b) External arch, c) Full support, d) Excavations, e) Others.~3. Hindfoot specifications: a) Heel cup, b) Supinator wedge, c) Pronating wedge, d) Lifter, e) Cup, f) Others.~4. Insole type and lining material~5. Materials of the added corrections~6. Insole base: a) soft ethylene vinyl acetate (eva), b) semi-soft eva, c) hard eva, d) rubber, e) cuerolite.
Study: NCT04244474

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A single one ml injection
Description: All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 \[18\], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) or placebo which is 1 ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code. (only office secretary aware of randomization codes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A single one ml injection
Description: All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 \[18\], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) or placebo which is 1 ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code. (only office secretary aware of randomization codes).
Study: NCT02348164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pink grapefruit first followed by tangerines two weeks later
Description: A 504 gram serving of pink grapefruit was fed as a single meal followed by 234 grams tangerines two weeks later

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tangerines first followed by pink grapefruit two weeks later
Description: A 234 gram serving of tangerines was fed as a single meal followed by 504 grams pink grapefruit two weeks later
Study: NCT04485403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 800 mg/day ( 2 x 400mg) for 3 weeks in women with a bodyweight \<70 kg, and a dose of 1200 mg/day (3x400mg) in women weighing\> 70kg. The effects of treatment will be compared on the basis of changes in the hormonal profile and inflammatory markers, as well as the clinical assessment of the patient.
Study: NCT03868436

Intervention type: DRUG
Group type: OTHER
Intervention: Methoxyflurane 3mL
Description: As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
Study: NCT01033175

Intervention type: PROCEDURE
Group type: OTHER
Intervention: peripheral blood samples
Description: Peripheral venous blood samples will be collected again in the morning after a fasting period of ≥12 hours. After immediate centrifugation, aliquots will be stored at -75˚C until analysis. Inflammatory markers and erythropoietin will be analyzed by flow cytometry and by enzyme-linked immunosorbent assay, using commercially available kits.
Study: NCT04116359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT02771067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid infusion
Description: Fluid infusion will be performed using 6% hydroxyethyl starch. Pulse pressure variation and stroke volume will be measured before and after fluid infusion.
Study: NCT04116359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molibresib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molibresib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molibresib Besylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molibresib Besylate
Description: Given PO
Study: NCT02341976

Intervention type: OTHER
Group type: OTHER
Intervention: Vibratory platform exercises
Description: Different positions on vibratory platform with different frequencies
Study: NCT02684591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Aramchol, a conjugate of Cholic acid and Arachidic acid, is a first in class member of a novel family of synthetic Fatty-Acid / Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds, orally administrated with potentially good safety and tolerability parameters

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03778216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Treatment
Study: NCT01923181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once-daily oral administration as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once-daily oral administration as tablets.
Study: NCT03314116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guidance on auditory protection
Description: by video or medic
Study: NCT01265914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FP-01.1
Description: Ascending doses of FP-01.1 will be administered
Study: NCT00730067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: Sildenafil 50 mg three times daily
Study: NCT01923181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once-daily oral administration as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once-daily oral administration as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once-daily oral administration as tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide
Description: Once-weekly,injected s.c./subcutaneously (under the skin) using a pen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo
Description: Once-daily oral administration as tablets.
Study: NCT02240082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based COPing with Shiftwork Program
Description: COPing with Shift Work is an interactive, web-based program designed specifically for law enforcement officers to assist with the management of health and lifestyle challenges associated with shift work. The program will contain modules on sleep, physical activity, and nutrition in order to improve the health and safety of law enforcement officers and reduce their risk of chronic diseases associated with shift work. These modules will contain interactive assessments and cutting-edge scientific information on sleep, nutrition, and physical activity. Based on user input, officers will receive personalized feedback, tools, and strategies
Study: NCT02855060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelvic Binder
Study: NCT00730067

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet with Laetose mono hydrat, talc,Potato tarch, Gelatin, Magnesium stearate.
Study: NCT04333277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Patients with major depression (both sexes) will receive capsules with 1 × 10\^9 CFUs of Lactobacillus helveticus in addition to a conventional antidepressant treatment for 8 weeks.
Study: NCT01265914

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04333277

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Patients with major depression (both sexes) will receive capsules of placebo (maltodextrin) in addition to a conventional antidepressant treatment for 8 weeks
Study: NCT02042482

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10U, L-carnitine
Study: NCT02375412

Intervention type: PROCEDURE
Intervention: Pre-operative measurement of heart rate variability
Description: Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery
Study: NCT04121962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentor
Description: Participants will be trained to be Peer Mentors and promote home-based testing to their social network

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Website only
Description: Participants will be given instructions on how to use the project website to request kits to test for HIV at home and collect specimens for lab testing.
Study: NCT04409756

Intervention type: OTHER
Group type: OTHER
Intervention: shoulder rating questionnaire
Description: to investigate reliability of turkish version of shoulder rating questionnaire
Study: NCT00335244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: 150mg bolus X 1 after initiation of cardiopulmonary bypass followed by continuous infusion of 9mg/kg/hr IV, starting 4 hours post bolus administration and ending at 48 hours continuous infusion or discharge from the PCCU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of intravenous L-citrulline
Description: Placebo of intravenous L-citrulline
Study: NCT01638416

Intervention type: OTHER
Group type: OTHER
Intervention: Blood transfusion
Description: Blood transfusion in ICU patients aged 18 and over.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Description: Blood transfusion in ICU patients aged 18 and over.
Study: NCT03243916

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TACE plus Cyber knife
Description: Patients with histologically confirmed MHCC(Massive Hepatocellular Carcinoma) will receive TACE therapy,after 1 or 2 week's recovery from hepatic insufficiency ,the targeted and staged cyber knife will be given
Study: NCT04842240

Intervention type: PROCEDURE
Intervention: Pre- or sub-pectoral implant based immediate breast reconstruction
Description: All study participants will undergo skin sparing mastectomy (with or without nipple preservation) for breast cancer or for risk reduction. Patients will undergo immediate breast reconstruction using an implant or a tissue expander. The device will be placed in pre- or sub-pectoral plane which will be supported by mesh (Tiloop/Surgimend Acellular Dermal Matrix) and/or a dermal flap.
Study: NCT01409694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine is administered to all participants according to the usual strategy, with upward titration of 5 mg per week during the first three weeks to reduce the risk of side effects. The final dosage is 20 mg per day, with no subsequent modification of dosage or specialty during the trial.
Study: NCT02995928

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy
Description: Decompressive craniectomy: All patients in the treatment group will receive decompressive craniectomy of at least 12 cm according to institutional guidelines and a published surgical protocol during the clipping surgery within 48 hours form the onset.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment
Description: Best medical treatment: Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2012 and 2013 respectively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Best medical treatment
Description: Best medical treatment: Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2012 and 2013 respectively.
Study: NCT02076113

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventral (Front) decompression with Fusion
Description: Ventral decompression and fusion will be performed using a multi-level discectomy (including partial or single level corpectomy) with fusion and plating. Allograft will be used at each disc space and all compressive osteophytes will be removed using the operating microscope. Fixation will be performed with rigid, semi-constrained, or dynamic titanium plates to optimize fusion and minimize complications.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal (Back) Decompression with Fusion
Description: Dorsal decompression and fusion will be performed using midline cervical laminectomy with the application of lateral mass screws and rods for rigid fixation. All surgeons will use local bone and allograft as needed to perform a lateral mass fusion, which typically will include one level rostral to the levels decompressed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal (back) Laminoplasty
Description: Laminoplasty will be performed using an open-door approach with the application of plates and screws at each treated level. Ceramic or allograft laminar spacers (surgeon's choice) can be used with plates and screws to expand the canal diameter.
Study: NCT01513759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator
Description: Participants will receive 24 mg of r-tPA delivered via the EkoSonic Endovascular Device.
Study: NCT01409694

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine
Description: Memantine is administered to all participants according to the usual strategy, with upward titration of 5 mg per week during the first three weeks to reduce the risk of side effects. The final dosage is 20 mg per day, with no subsequent modification of dosage or specialty during the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Subjects receive Vitamin D supplementation (cholecalciferol 100,000 IU, drinking solution, 2 mL vial) at a rate of 1 drinking vial of 100,000 IU cholecalciferol every month. In brief, the total dose is 600,000 IU over the duration of the study starting with one vial at the time of inclusion, then at week(W) 4, W8, W12, W16 and W20. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study.
Study: NCT01513759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EKOS EkoSonic Endovascular System
Description: 24 mg of r-tPA will be delivered through the EkoSonic Endovascular System.
Study: NCT03237481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX 011 (bupivacaine/meloxicam), 300 mg/9 mg by instillation
Study: NCT01409694

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D placebo
Description: Subjects receive Vitamin D placebo (drinking solution, 2mL vial) at a rate of 1 drinking vial every month. In brief, the subjects start with one vial at the time of inclusion, then at week(W)4, W8, W12, W16 and W20. The placebo drinking solution contains all the excipients present in the Vitamin D vial.
Study: NCT04332744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide capsules orally once daily and continuously (160 mg) in 28-day cycles (every four weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide capsules orally once daily and continuously (160 mg) in 28-day cycles (every four weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib capsules orally once daily and continuously (0.5 mg) in 28-day cycles (every four weeks)
Study: NCT01266239

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kissing balloon inflation
Description: Kissing balloon inflation following the MV stenting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kissing balloon inflation
Description: Kissing balloon inflation following the MV stenting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kissing balloon inflation
Description: Kissing balloon inflation following the MV stenting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kissing balloon inflation
Description: Kissing balloon inflation following the MV stenting

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EES vs. SES
Description: Rapid endothelialization after EES deployment has been reported compared to that after SES deployment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EES vs. SES
Description: Rapid endothelialization after EES deployment has been reported compared to that after SES deployment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EES vs. SES
Description: Rapid endothelialization after EES deployment has been reported compared to that after SES deployment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EES vs. SES
Description: Rapid endothelialization after EES deployment has been reported compared to that after SES deployment.
Study: NCT03037944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yasmin
Description: (ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metraplant-E
Description: Levonorgestrel-releasing Intrauterine System modified levonorgestrel-releasing intrauterine system from the old IUD Metraplant, modified by Azzam 2013
Study: NCT03981003

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: 2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels